No, a Single Dose of Hepatitis B Vaccine is Not Sufficient
A patient with chronic plaque psoriasis on risankizumab requires a complete hepatitis B vaccination series (typically 3 doses), not just a single dose, to induce protective immunity and allow meaningful assessment of immune response. 1
Vaccination Schedule for Immunocompromised Patients
Patients receiving immunosuppressive therapy for rheumatologic or gastroenterologic disorders (which includes psoriasis patients on biologics like risankizumab) are specifically identified as requiring:
- Complete 3-dose primary series at 0,1, and 6 months 1
- Post-vaccination serologic testing 1-2 months after the final (third) dose to document protective anti-HBs levels (≥10 mIU/mL) 1
The CDC ACIP guidelines explicitly state that persons needing immunosuppressive therapy should receive serologic testing prior to vaccination, and the first dose should be administered immediately after blood collection for testing 1. However, protective immunity cannot be reliably assessed after just one dose - the complete series is required.
Why the Complete Series Matters
The immunologic rationale is clear:
- The third dose confers maximum seroprotection and provides long-term protection 1
- Longer intervals between the last two doses result in higher final antibody levels 1
- Anti-HBs ≥10 mIU/mL as a correlate of vaccine-induced protection has only been determined for persons who completed an approved vaccination series 1
Special Considerations for Risankizumab Patients
While risankizumab (an IL-23 inhibitor) appears to have a favorable safety profile regarding HBV reactivation risk 2, 3, patients on this therapy still require:
- Pre-treatment HBV screening (HBsAg, anti-HBc, anti-HBs) 1
- Complete vaccination series if susceptible
- Post-series antibody testing to confirm adequate response 1
Research suggests that IL-23 inhibitors like risankizumab may carry lower infection risk compared to TNF inhibitors 3, but this does not change the fundamental requirement for complete vaccination.
If Response is Inadequate After Primary Series
For immunocompromised patients who fail to achieve anti-HBs ≥10 mIU/mL after the primary 3-dose series 1:
- Administer a second complete 3-dose series (total 6 doses)
- Retest anti-HBs 1-2 months after the final dose
- Consider higher-dose vaccine (40 μg vs standard 20 μg) for better response in immunocompromised patients 4
Common Pitfall to Avoid
Do not test anti-HBs after a single dose and assume this reflects vaccine-induced protection. Testing after incomplete vaccination is "potentially misleading" per CDC guidelines 1, as the correlate of protection has only been validated after complete series.
The patient needs all 3 doses before you can reliably assess their immune profile and determine if they have achieved protective immunity.